Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Esperion Therapeutics Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ESPR
Nasdaq
2834
https://www.esperion.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Esperion Therapeutics Inc
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- May 10th, 2024 8:00 pm
Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
- May 8th, 2024 4:20 pm
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript
- May 8th, 2024 3:08 pm
Esperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...
- May 8th, 2024 7:04 am
Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
- May 7th, 2024 4:20 pm
Esperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% Increase
- May 7th, 2024 12:55 pm
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
- May 7th, 2024 11:15 am
Esperion Reports First Quarter 2024 Financial Results
- May 7th, 2024 10:00 am
Esperion to Participate in Upcoming May Investor Conferences
- Apr 29th, 2024 12:00 pm
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
- Apr 25th, 2024 1:00 pm
Esperion to Report First Quarter 2024 Financial Results on May 7
- Apr 23rd, 2024 12:00 pm
11 Best Low Price Pharma Stocks To Invest In
- Apr 21st, 2024 2:39 pm
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
- Apr 7th, 2024 6:45 pm
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
- Apr 1st, 2024 12:00 pm
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
- Mar 28th, 2024 3:30 pm
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
- Mar 26th, 2024 12:00 pm
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
- Mar 25th, 2024 8:00 pm
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- Mar 22nd, 2024 10:26 pm
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
- Mar 22nd, 2024 7:10 pm
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
- Mar 22nd, 2024 3:04 pm
Scroll